TSS
KTTAW icon

Two Sigma Securities’s Pasithea Therapeutics Warrants KTTAW Stock Holding History

Two Sigma Securities’s Portfolio KTTAW Stock Details KTTAW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$556 Buy
55,644
+65
+0.1% +$1 ﹤0.01% 1582
2025
Q4 		$784 Buy
+55,579
New +$1.22K ﹤0.01% 1391

Other funds holding KTTAW

KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
MG
Marex Group London $15.8B AUM 31.44% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Two Sigma Securities's KTTAW Position: Q1 2026 in Review

Two Sigma Securities increased its Pasithea Therapeutics Warrants (KTTAW) stake by 0.12% in Q1 2026, buying an estimated $1 and bringing the position to 55,644 shares worth $556. The position accounts for ﹤0.01% of the portfolio, ranked #1582.

Two Sigma Securities first reported a position in KTTAW in Q4 2025 and has held it in 2 quarters since. The position peaked at $784 in Q4 2025. 5 funds tracked by Wall St. Rank hold KTTAW as of Q1 2026.

  • Two Sigma Securities held 55,644 shares of Pasithea Therapeutics Warrants worth $556 as of Q1 2026.
  • Two Sigma Securities bought 65 Pasithea Therapeutics Warrants shares in Q1 2026, an estimated $1.
  • Pasithea Therapeutics Warrants made up ﹤0.01% of Two Sigma Securities's portfolio in Q1 2026, its #1582 holding.
  • Two Sigma Securities first reported a position in Pasithea Therapeutics Warrants in Q4 2025 and has held it in 2 quarters since.
  • Two Sigma Securities's Pasithea Therapeutics Warrants position peaked at $784 in Q4 2025.
  • 5 funds tracked by Wall St. Rank held Pasithea Therapeutics Warrants as of Q1 2026.

Based on Two Sigma Securities's 13F filing for Q1 2026, filed 15 May 2026.